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ctrial fibrillation (AF) is a progressive disease. In patients
ith paroxysmal AF at initial clinical evaluation, progres-
ion to persistent forms is documented in approximately
0% at 1 year, 25% to 30% at 5 years, and 50% beyond 10
ears despite pharmacologic therapy (1–6). Once AF be-
omes persistent, maintenance of sinus rhythm becomes
ore difficult. In patients with persistent AF of 1 year
uration, only 40% to 60% of patients remain in sinus
hythm 1 year after initiation of treatment, despite multiple
ardioversions and antiarrhythmic drugs, with additional
elapses over the subsequent years (7–11). Duration of
ersistent AF 3 years is associated with a 15% proba-
ility of long-term sinus rhythm (11). Electrical, contractile,
nd structural remodeling of the atria occur in parallel with
he increasing frequency and duration of AF, facilitating AF
tability and persistence (12). The latter includes progressive
hanges in cellular ultrastructure and extracellular matrix
olume and composition, mediated by a complex set of
ignaling mechanisms, and ultimately resulting in myocyte
oss and interstitial fibrosis (13,14). The extent to which
tructural remodeling is reversible, and the optimal timing
nd tools for clinical intervention, remain poorly defined.
See page 788
Although therapy for persistent AF is usually undertaken
or control of symptoms most immediately related to AF
palpitations, dyspnea, exercise intolerance), the association
etween AF and other adverse long-term outcomes, includ-
ng death, stroke, and heart failure, is well established
15–17). Evidence to date from large-scale clinical trials does
ot support the concept that these latter risks can be amelio-
ated or reversed by a proactive strategy directed toward sinus
hythmmaintenance (7–10,18); these outcomesmay reflect the
neffectiveness and toxicity of antiarrhythmic drug therapy
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.g
From the Cardiovascular Institute, Loyola University Medical Center, Maywood,
llinois.ather than a failure of strategy. Retrospective data indicate that
hen sinus rhythm can be maintained by drugs or catheter
blation, morbidity and mortality related to AF may be
ignificantly reduced (19–21).
Collectively, these considerations have led many clini-
ians to advocate earlier intervention to reverse or retard
trial remodeling before long-term maintenance of sinus
hythm becomes improbable, either before AF has become
ersistent or relatively soon thereafter. Catheter ablation
rovides a promising alternative to antiarrhythmic therapy,
nd in experienced centers, is reported to result in sinus
hythm maintenance in 60% to 90% of selected patients
ith persistent AF without antiarrhythmic drugs during
ollow-up of 1 to 2 years (22–26). Termination of persistent
F during ablation in this population is technically chal-
enging, and multiple procedures may be required to effect
urable maintenance of sinus rhythm. More extensive sub-
trate modification in the left or both atria, in addition to
he pulmonary vein isolation, seems necessary to optimize
ong-term success, consistent with progressive structural
emodeling (24–27). Critical, but as yet unanswered, ques-
ions remain: How do we identify patients in whom
tructural remodeling has become irreversible? When is it
oo late to intervene? The study by Matsuo et al. (28),
ublished in this issue of the Journal, provides important, if
reliminary, answers.
The investigators examined the predictors of sinus
hythm maintenance in a group of 90 patients undergoing
nitial ablation of persistent AF (1 month duration). The
ean and median duration of continuous AF before the
rocedure were 28 and 19 months, respectively, and 3
ears in 25% of patients. The study population was young
mean age 57 years), with a lower incidence of structural
eart disease (28%) and hypertension (27%) compared with
he general population with persistent AF (7–11). Ablation
as performed using a stepwise approach involving pulmo-
ary vein isolation followed by ablation at LA sites showing
bnormal electrograms (continuous fractionation, rapid and
omplex fractionated electrograms, or temporal activation
radients), a roof line, and a mitral isthmus line successively
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August 25, 2009:796–8 Sinus Rhythm and Persistent AFf AF had not terminated. Overall, AF was terminated by
blation in 84% of patients. At least 1 repeat procedure was
erformed in a majority of patients (mean 1.8 procedures/
atient, range 1 to 4 procedures/patient). Antiarrhythmic
rug therapy was stopped 1 to 3 months after the baseline
rocedure.
In addition to well-known predictors of sinus rhythm
aintenance from previous long-term outcome studies (age,
uration of AF, left atrial size, presence of structural heart
isease), the investigators examined the predictive value of
lobal AF cycle length (CL) as determined from short
egments of surface electrocardiogram (ECG) lead V1 by
ime-frequency analysis. The utility of this and related
pproaches in characterizing AF organization, and the
otential extent of structural remodeling, has become in-
reasingly apparent over the past decade (29,30). The
nvestigators provide new evidence that a relatively simple
anual measurement of AFCL from the surface ECG
ould be obtained in the vast majority of patients, and that
his measure was highly correlated with more sophisticated
eterminations of CL by computerized algorithm.
Long-term success was defined as absence of a recurrent
trial tachyarrhythmia3 min in duration without concom-
tant antiarrhythmic drugs during the 18  6-month
ollow-up after the final ablation procedure. This end point
as achieved in 84% of patients. Using receiver-operator
haracteristic curves to identify optimal cut points, the
nvestigators found that both AFCL and AF duration were
owerful and independent predictors of both AF termina-
ion during the index procedure and long-term maintenance
f sinus rhythm after the final procedure. At 1 year, sinus
hythm was maintained in approximately 93% of patients
ith AFCL 142 ms compared with only approximately
8% in patients with an AFCL 142 ms. In patients with
21 months of continuous AF before the index ablation,
inus rhythm was maintained in only approximately 72% of
atients, compared with approximately 95% in patients with
duration 21 months. Of interest, the majority of
ecurrent arrhythmias after the baseline procedure were
trial tachycardias, which were successfully ablated during
epeat procedures. Recurrence of AF after the baseline
rocedure was associated with a low probability of sinus
hythm maintenance during follow-up (3 of 16 patients),
espite repeat ablation.
How should these data impact the referral of patients
ith persistent AF for catheter ablation? The investigators
onclude that ablation of persistent AF2 years in duration
s associated with a high rate of sinus rhythm maintenance,
nd patients should be referred within this time frame for
ptimal results. For patients with longer or unknown
uration of AF, additional evaluation of the surface ECG
FCL can guide selection of those most likely to benefit.
hese guidelines are attractive in their simplicity, in that the
ecessary data can be readily obtained from an initial
utpatient visit without extensive additional testing.However, there are several reasons to consider these
uidelines as tentative and preliminary. Notably, in this
tudy, other previously identified predictors of sinus rhythm
aintenance had minimal or no impact on the long-term
utcome of ablation. This finding may reflect a trend toward
electing a more homogenous population of younger pa-
ients with less extensive comorbidity for ablation; some
aution is warranted in generalizing these results to the
eneral population with persistent AF. There are few data
rom this or previous studies regarding the risk of recur-
ences after the initial 1 or 2 years in sinus rhythm.
aintenance of sinus rhythm after ablation may also differ
y procedural technique, particularly with less extensive
blation than that used by Matsuo et al. (28). The investi-
ators do not provide data on the use of concurrent drugs
hat target potential mediators of structural remodeling
angiotensin converting enzyme inhibitors, angiotensin II
eceptor blockers, aldosterone antagonists, and statins), and
ay favorably influence rhythm control (31,32). Finally, use
f alternative surface ECG indexes of AF organization and
omplexity (30), biomarkers of ongoing structural remodel-
ng (33), or direct imaging of the extent and distribution of
trial fibrosis (34) may further refine our predictions of
uccessful outcomes.
Accumulating data support the concept of intervention
elatively early in the course of persistent AF to ensure a
easonable probability of maintaining sinus rhythm over
ubsequent years. Whether catheter ablation will provide a
ore effective approach than antiarrhythmic therapy to
ccomplish this task, and reduce attendant morbidity and
ortality, is the subject of a recently initiated 3,000-patient
ulticenter trial, CABANA (Catheter ABlation versus
Ntiarhythmic Drug Therapy for Atrial Fibrillation).
owever, clinicians considering ablation therapy for persis-
ent AF need to be mindful of the potential limitations in
vercoming or reversing structural remodeling. The data of
atsuo et al. (28) provide a useful and practical first step in
hese deliberations.
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oom 6232, Building 110, Loyola University Medical Center,
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